Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ongericimab for Prevention of Recurrent Ischemic Stroke
ChiCTR2600123198Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ongericimab in ischemic stroke, cerebrovascular disease and atherosclerotic disease (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Composite major cardiovascular events and Serious adverse events. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ongericimab
03
Conditions
ischemic strokecerebrovascular diseaseatherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2600123198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123198.